
1. Hepatology. 2018 Jul;68(1):32-47. doi: 10.1002/hep.29814. Epub 2018 Apr 27.

All-oral direct-acting antiviral therapy against hepatitis C virus (HCV) in human
immunodeficiency virus/HCV-coinfected subjects in real-world practice: Madrid
coinfection registry findings.

Berenguer J(1), Gil-Martin Á(2), Jarrin I(3), Moreno A(4), Dominguez L(5), Montes
M(6), Aldámiz-Echevarría T(1), Téllez MJ(7), Santos I(8), Benitez L(9), Sanz
J(10), Ryan P(11), Gaspar G(12), Alvarez B(13), Losa JE(14), Torres-Perea R(15), 
Barros C(16), Martin JVS(17), Arponen S(18), de Guzmán MT(19), Monsalvo R(20),
Vegas A(21), Garcia-Benayas MT(22), Serrano R(23), Gotuzzo L(24), Menendez
MA(25), Belda LM(26), Malmierca E(27), Calvo MJ(2), Cruz-Martos E(2),
González-García JJ(6).

Author information: 
(1)Hospital General Universitario Gregorio Marañón/IiSGM, Madrid, Spain.
(2)Subdirección General de Farmacia y Productos Sanitarios/SERMAS, Madrid, Spain.
(3)Instituto de Salud Carlos III, Madrid, Spain.
(4)Hospital Universitario Ramón y Cajal, Madrid, Spain.
(5)Hospital Universitario 12 de Octubre/i+12, Madrid, Spain.
(6)Hospital La Paz/IdiPaz, Madrid, Spain.
(7)Hospital Clínico Universitario San Carlos, Madrid, Spain.
(8)Hospital Universitario de la Princesa, Madrid, Spain.
(9)Hospital Universitario Puerta de Hierro, Majadahonda, Spain.
(10)Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain.
(11)Hospital Universitario Infanta Leonor, Madrid, Spain.
(12)Hospital Universitario de Getafe, Getafe, Spain.
(13)Fundación Jiménez Díaz, Madrid, Spain.
(14)Fundación Hospital de Alcorcón, Alcorcón, Spain.
(15)Hospital Universitario Severo Ochoa, Leganés, Spain.
(16)Hospital Universitario de Móstoles, Móstoles, Spain.
(17)Hospital Universitario de Fuenlabrada, Fuenlabrada, Spain.
(18)Hospital de Torrejón, Torrejón de Ardoz, Spain.
(19)Hospital Infanta Cristina, Parla, Spain.
(20)Hospital del Tajo, Aranjuez, Madrid, Spain.
(21)Hospital Infanta Elena, Valdemoro, Spain.
(22)Hospital Universitario del Sureste, Arganda, Spain.
(23)Hospital del Henares, Coslada, Spain.
(24)Hospital Rey Juan Carlos, Móstoles, Spain.
(25)Hospital Gómez Ulla, Madrid, Spain.
(26)Hospital del Escorial, El Escorial, Spain.
(27)Hospital Infanta Sofía, San Sebastián de los Reyes, Spain.

We evaluated treatment outcomes in a prospective registry of human
immunodeficiency virus/hepatitis C virus (HCV)-coinfected patients treated with
interferon-free direct-acting antiviral agent-based therapy in hospitals from the
region of Madrid between November 2014 and August 2016. We assessed sustained
viral response at 12 weeks after completion of treatment and used multivariable
logistic regression to identify predictors of treatment failure. We evaluated
2,369 patients, of whom 59.5% did not have cirrhosis, 33.9% had compensated
cirrhosis, and 6.6% had decompensated cirrhosis. The predominant HCV genotypes
were 1a (40.9%), 4 (22.4%), 1b (15.1%), and 3 (15.0%). Treatment regimens
included sofosbuvir (SOF)/ledipasvir (61.9%), SOF plus daclatasvir (14.6%),
dasabuvir plus ombitasvir/paritaprevir/ritonavir (13.2%), and other regimens
(10.3%). Ribavirin was used in 30.6% of patients. Less than 1% of patients
discontinued therapy owing to adverse events. The frequency of sustained viral
response by intention-to-treat analysis was 92.0% (95% confidence interval,
90.9%-93.1%) overall, 93.8% (92.4%-95.0%) for no cirrhosis, 91.0% (88.8%-92.9%)
for compensated cirrhosis, and 80.8% (73.7%-86.6%) for decompensated cirrhosis.
The factors associated with treatment failure were male sex (adjusted odds ratio,
1.75; 95% confidence interval, 1.14-2.69), Centers for Diseases Control and
Prevention category C (adjusted odds ratio, 1.65; 95% confidence interval,
1.12-2.41), a baseline cluster of differentiation 4-positive (CD4+) T-cell count 
<200/mm3 (adjusted odds ratio, 2.30; 95% confidence interval, 1.35-3.92), an HCV 
RNA load ≥800,000 IU/mL (adjusted odds ratio, 1.63; 95% confidence interval,
1.14-2.36), compensated cirrhosis (adjusted odds ratio, 1.35; 95% confidence
interval, 0.96-1.89), decompensated cirrhosis (adjusted odds ratio, 2.92; 95%
confidence interval, 1.76-4.87), and the use of SOF plus simeprevir, SOF plus
ribavirin, and simeprevir plus daclatasvir.CONCLUSION: In this large real-world
study, direct-acting antiviral agent-based therapy was safe and highly effective 
in coinfected patients; predictors of failure included gender, human
immunodeficiency virus-related immunosuppression, HCV RNA load, severity of liver
disease, and the use of suboptimal direct-acting antiviral agent-based regimens. 
(Hepatology 2018;68:32-47).

© 2018 The Authors. Hepatology published by Wiley Periodicals, Inc., on behalf of
the American Association for the Study of Liver Diseases.

DOI: 10.1002/hep.29814 
PMCID: PMC6055848
PMID: 29377274  [Indexed for MEDLINE]

